ARTICLE | Clinical News

NBI-98854: Phase III started

November 3, 2014 8:00 AM UTC

Neurocrine began the double-blind, U.S. Phase III Kinect 3 Study to evaluate once-daily oral NBI-98854 in about 240 patients with underlying schizophrenia, schizoaffective disorder or mood disorder. Patients will receive 40 or 80 mg NBI-98854 or placebo for 6 weeks and will then be randomized to receive 40 or 80 mg NBI-98854 in a double-blind treatment period for an additional 42 weeks. ...